Table 2 from Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010)

Activity according to biomarker subgroups: PFS (median, IQR, months).基于生物标志物亚组（biomarker subgroups）的疗效数据：无进展生存期（Progression-Free Survival, PFS），以中位数、四分位距（Interquartile Range, IQR）为统计指标，单位为月。